New mutations in TP53 gene drive resistance to p53-targeted cancer therapy

Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for ...
The American Journal of Managed Care

TP53 Mutations Remain Important Research Focus in Cancer

TP53 mutations are crucial in cancer development and treatment response, influenced by genetic and environmental factors. In CLL and AML, TP53 serves as a significant prognostic marker, affecting ...
News Medical

Researchers uncover why the TP53 gene is especially prone to mutations in cancer

In a recent perspective published in the journal Cell Death and Differentiation, researchers in France, Germany, and Sweden discussed the unique mutational spectrum of the transformation-related ...

Liquid biopsy advances could yield new tool for detecting lung cancer mutations

In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for ...
The American Journal of Managed Care

Multi-Hit TP53 Mutations Linked With Poor Outcomes in MPN, AML

Multi-hit TP53 mutations are linked to poor survival in both MPN and AML, with median OS ranging from 4.8 to 11.6 months. Factors such as ASCT, pre-transplant therapy response, and concurrent TET2 or ...
ascopubs.org

Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D ...

Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study Authors retain all rights in any ...